ProCE Banner Activity

Improving Outcomes in Major Depression: Focus on Individualizing Treatment

Slideset Download
Slides from the major depressive disorder presentation at the 2022 Psychopharmacology Update conference.

Released: December 01, 2022

Begin Activity

Share

Faculty

Greg W. Mattingly

Greg W. Mattingly, MD

Greg W. Mattingly, MD

Associate Clinical Professor

Department of Psychiatry

Washington University School of Medicine

President

St. Charles Psychiatry Associates

St. Louis, Missouri

Supporters

Supported by an educational grant from

AbbVie Inc

Faculty Disclosure

Primary Author

Greg W. Mattingly, MD

Greg W. Mattingly, MD

Associate Clinical Professor

Department of Psychiatry

Washington University School of Medicine

President

St. Charles Psychiatry Associates

St. Louis, Missouri

Greg W. Mattingly, MD: consultant/advisor/speaker: AbbVie, Acadia, Alkermes, Axsome, Corium, Eisai, Ironshore, Intracellular, Janssen, Lundbeck, Neos, Neurocrine, Noven, Otsuka, Redax, Roche, Rhodes, Sage, Sirona, Sunovion, Supernus, Takeda, Teva, Trispharma; researcher: AbbVie, Acadia, Alkermes, Akili, Axsome, Boehringer Ingelheim, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, NLS-1 Pharma AG, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, Teva.